Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) 是人源化的 IgG4,κ 抗体靶向人 CD22。Inotuzumab 与毒素奥加米星 (ozogamicin) 相连接可作为抗体-活性分子偶联物 (ADC)。Inotuzumab 可于急性淋巴细胞白血病和非霍奇金淋巴瘤的研究。
此产品仅用于科学研究,我们不为任何个人用途提供产品和服务
Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) is a humanized CD22. Inotuzumab can be linked to a toxic agent ozogamicin as an antibody-drug conjugate (ADC). Inotuzumab can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma[1].
[1]. Aujla A, et al. Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma. Biomark Res. 2019 Apr 11;7:9.
DMNPE-caged ATP diammonium salt
¥3870.00 ¥4837.00
没有评价数据